TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Collaborative Care for Substance Use Disorders
Brief Summary: Primary care settings (PCS) are a missed opportunity for delivering evidence-based treatments for opiate and alcohol-use disorders (OAUD). The investigators propose to evaluate the costs and effectiveness of two strategies to increase the delivery of OAUD treatments in PCS, integrated collaborative care (ICC) and education and resources (E\&R). The investigators hypothesize that ICC will be more effective than E\&R in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes.

Results from our study will help providers choose between two different strategies and advance the field of implementation research.


Options:
A: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Regimen A calcium and iron/folic acid | Arm Label: Regimen B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Regimen B calcium and iron/folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen A calcium and iron/folic acid; Assigned to Arm(s): Regimen A | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen B calcium and iron/folic acid; Assigned to Arm(s): Regimen B
B: Arm Label: PrEP Prescription at Enrollment; Type: N/A; Interventions: N/A | Arm Label: No PrEP Prescription at Enrollment; Type: N/A; Interventions: N/A
C: Arm Label: Meta Salud Diabetes-Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Education intervention | Arm Label: Meta Salud Diabetes-Comparison Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Education intervention; Assigned to Arm(s): Meta Salud Diabetes-Intervention
D: Arm Label: ICC; Type: EXPERIMENTAL; Interventions: Other: Integrated collaborative care | Arm Label: E&R; Type: ACTIVE_COMPARATOR; Interventions: Other: Education and Resources | Intervention Type: OTHER; Name: Integrated collaborative care; Assigned to Arm(s): ICC | Intervention Type: OTHER; Name: Education and Resources; Assigned to Arm(s): E&R

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Collaborative Care for Substance Use Disorders
Brief Summary: Primary care settings (PCS) are a missed opportunity for delivering evidence-based treatments for opiate and alcohol-use disorders (OAUD). The investigators propose to evaluate the costs and effectiveness of two strategies to increase the delivery of OAUD treatments in PCS, integrated collaborative care (ICC) and education and resources (E\&R). The investigators hypothesize that ICC will be more effective than E\&R in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes.

Results from our study will help providers choose between two different strategies and advance the field of implementation research.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx) | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone maintenance (Mtn); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Behavioral: Buprenorphine/naloxone detoxification (Dtx); Assigned to Arm(s): 2
B: Arm Label: Naltrexone intramuscular suspension; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone intramuscular suspension | Arm Label: Buprenorphine-naloxone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buprenorphine-naloxone | Intervention Type: DRUG; Name: Naltrexone intramuscular suspension; Assigned to Arm(s): Naltrexone intramuscular suspension | Intervention Type: DRUG; Name: Buprenorphine-naloxone; Assigned to Arm(s): Buprenorphine-naloxone
C: Arm Label: ICC; Type: EXPERIMENTAL; Interventions: Other: Integrated collaborative care | Arm Label: E&R; Type: ACTIVE_COMPARATOR; Interventions: Other: Education and Resources | Intervention Type: OTHER; Name: Integrated collaborative care; Assigned to Arm(s): ICC | Intervention Type: OTHER; Name: Education and Resources; Assigned to Arm(s): E&R
D: Arm Label: Methadone Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: Holistic Health Recovery Program; Type: EXPERIMENTAL; Interventions: Behavioral: Holistic Health Recovery Program | Arm Label: Methadone Maintenance and Holistic Health Recovery Prorgram; Type: EXPERIMENTAL; Interventions: Drug: Methadone, Behavioral: Holistic Health Recovery Program | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone Maintenance, Methadone Maintenance and Holistic Health Recovery Prorgram | Intervention Type: BEHAVIORAL; Name: Holistic Health Recovery Program; Assigned to Arm(s): Holistic Health Recovery Program, Methadone Maintenance and Holistic Health Recovery Prorgram

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Collaborative Care for Substance Use Disorders
Brief Summary: Primary care settings (PCS) are a missed opportunity for delivering evidence-based treatments for opiate and alcohol-use disorders (OAUD). The investigators propose to evaluate the costs and effectiveness of two strategies to increase the delivery of OAUD treatments in PCS, integrated collaborative care (ICC) and education and resources (E\&R). The investigators hypothesize that ICC will be more effective than E\&R in promoting A. Implementation outcomes B. Service system outcomes and C. Patient outcomes.

Results from our study will help providers choose between two different strategies and advance the field of implementation research.


Options:
A: Arm Label: Best practices primary care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Best practices primary care | Arm Label: Home based occupational therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Home based occupational therapy | Intervention Type: BEHAVIORAL; Name: Home based occupational therapy; Assigned to Arm(s): Home based occupational therapy | Intervention Type: BEHAVIORAL; Name: Best practices primary care; Assigned to Arm(s): Best practices primary care
B: Arm Label: Arm 1; Type: OTHER; Interventions: Procedure: System level depression care quality improvement | Intervention Type: PROCEDURE; Name: System level depression care quality improvement; Assigned to Arm(s): Arm 1
C: Arm Label: ICC; Type: EXPERIMENTAL; Interventions: Other: Integrated collaborative care | Arm Label: E&R; Type: ACTIVE_COMPARATOR; Interventions: Other: Education and Resources | Intervention Type: OTHER; Name: Integrated collaborative care; Assigned to Arm(s): ICC | Intervention Type: OTHER; Name: Education and Resources; Assigned to Arm(s): E&R
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The "START" (a Streamlined ART Initiation Strategy) Study
Brief Summary: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2) targeted knowledge transfer (i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3) feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.


Options:
A: Intervention Type: PROCEDURE; Name: Quality Initiative in Rectal Cancer (QIRC) strategy; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Lifestyle Counselling; Opinion Leader Influence Statements; Assigned to Arm(s): N/A
C: Arm Label: MJAP Clinics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: START | Arm Label: MJAP Clinics Pre-Intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: START; Assigned to Arm(s): MJAP Clinics Intervention
D: Arm Label: Educational Outreach Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Outreach Visits | Arm Label: Passive Dissemination; Type: ACTIVE_COMPARATOR; Interventions: Other: Passive Dissemination | Intervention Type: BEHAVIORAL; Name: Educational Outreach Visits; Assigned to Arm(s): Educational Outreach Visits | Intervention Type: OTHER; Name: Passive Dissemination; Assigned to Arm(s): Passive Dissemination

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Uninational, Multicenter, Two Parallel Groups, Active Controlled Study to Compare the Effect of the Treatment With Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation
Brief Summary: The study design combines a long-term safety and a dose range determination objective. The first 8 weeks of the study were primarily intended for the dose range determination, while the later visits were used for the comparison of long-term safety between the groups.


Options:
A: Arm Label: Macrogol (Transipeg); Type: EXPERIMENTAL; Interventions: Drug: Macrogol (Transipeg, BAY81-8430) | Arm Label: Macrogol (Forlax); Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrogol (Forlax) | Intervention Type: DRUG; Name: Macrogol (Transipeg, BAY81-8430); Assigned to Arm(s): Macrogol (Transipeg) | Intervention Type: DRUG; Name: Macrogol (Forlax); Assigned to Arm(s): Macrogol (Forlax)
B: Arm Label: PEG-only; Type: EXPERIMENTAL; Interventions: Device: Polyethylene glycol | Arm Label: PEG-EL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol with electrolytes | Intervention Type: DRUG; Name: Polyethylene glycol with electrolytes; Assigned to Arm(s): PEG-EL | Intervention Type: DEVICE; Name: Polyethylene glycol; Assigned to Arm(s): PEG-only
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PEG 4000 (Forlax®) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactulose active and Lactulose placebo | Intervention Type: DRUG; Name: PEG 4000 (Forlax®); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Lactulose active and Lactulose placebo; Assigned to Arm(s): 2
D: Arm Label: Polyethylene glycol small dose; Type: EXPERIMENTAL; Interventions: Drug: Polyethylene glycol 4000 | Arm Label: Polyethylene glycol high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol 4000 | Intervention Type: DRUG; Name: Polyethylene glycol 4000; Assigned to Arm(s): Polyethylene glycol high dose, Polyethylene glycol small dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: STELLA Trial: Staging of Endometrial and Ovarian Cancer Comparing the Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Lymphadenectomy of Aortic Nodes
Brief Summary: The purpose of this study is to determine whether the extraperitoneal approach is better than the transperitoneal approach for laparoscopic aortic lymphadenectomy for the surgical staging of endometrial or ovarian cancer.


Options:
A: Arm Label: Robotic surgery; Type: EXPERIMENTAL; Interventions: Procedure: Robotic surgery | Arm Label: Abdominal surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Abdominal surgery | Intervention Type: PROCEDURE; Name: Robotic surgery; Assigned to Arm(s): Robotic surgery | Intervention Type: PROCEDURE; Name: Abdominal surgery; Assigned to Arm(s): Abdominal surgery
B: Arm Label: Transperitoneal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transperitoneal laparoscopic aortic lymphadenectomy | Arm Label: Extraperitoneal; Type: EXPERIMENTAL; Interventions: Procedure: Extraperitoneal laparoscopic aortic lymphadenectomy | Intervention Type: PROCEDURE; Name: Transperitoneal laparoscopic aortic lymphadenectomy; Assigned to Arm(s): Transperitoneal | Intervention Type: PROCEDURE; Name: Extraperitoneal laparoscopic aortic lymphadenectomy; Assigned to Arm(s): Extraperitoneal
C: Arm Label: Robotic Surgery; Type: EXPERIMENTAL; Interventions: Procedure: Robotic surgery | Arm Label: Laparoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Surgery | Intervention Type: PROCEDURE; Name: Robotic surgery; Assigned to Arm(s): Robotic Surgery | Intervention Type: PROCEDURE; Name: Laparoscopic Surgery; Assigned to Arm(s): Laparoscopy
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: robotic laparoscopic sacrocolpopexy | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Sacral Colpopexy | Intervention Type: PROCEDURE; Name: robotic laparoscopic sacrocolpopexy; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Laparoscopic Sacral Colpopexy; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia
Brief Summary: The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium). The study also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer treatment was also evaluated.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zirconium silicate (ZS); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (ZS) | Intervention Type: DRUG; Name: Zirconium silicate (ZS); Assigned to Arm(s): Zirconium silicate (ZS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group 1 - Dosing Without Food; Type: EXPERIMENTAL; Interventions: Drug: patiromer | Arm Label: Group 2 - Dosing With Food; Type: ACTIVE_COMPARATOR; Interventions: Drug: patiromer | Intervention Type: DRUG; Name: patiromer; Assigned to Arm(s): Group 1 - Dosing Without Food, Group 2 - Dosing With Food
C: Arm Label: Patiromer; Type: ACTIVE_COMPARATOR; Interventions: Drug: Patiromer | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Patiromer Oral Powder Product; Type: EXPERIMENTAL; Interventions: Drug: Patiromer Oral Powder Product | Arm Label: Usual care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Patiromer Oral Powder Product; Assigned to Arm(s): Patiromer Oral Powder Product

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Synbiotics in Infants With Cyanotic Congenital Heart Disease
Brief Summary: Infants with congenital heart disease have more frequent infections and exposures to antibiotics than healthy infants. The investigators hypothesized that synbiotics may reduce the rate of sepsis and necrotizing enterocolitis in infants with CHD


Options:
A: Arm Label: Probiotics; Type: N/A; Interventions: N/A
B: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control
C: Arm Label: Bifidobacterium lactis plus inulin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Arm Label: maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis plus inulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis plus inulin; Assigned to Arm(s): maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Bifidobacterium lactis plus inulin
D: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion
Brief Summary: This study will test ways to give women more options and flexibility when they are ending their unwanted pregnancies. The investigators will look at uptake and acceptability of using mifepristone outside of the clinic for pregnancy termination.


Options:
A: Arm Label: clinic administration of mifepristone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: home administration of mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): home administration of mifepristone
B: Arm Label: mifepristone+misoprostol; Type: EXPERIMENTAL; Interventions: Drug: mifepristone, Drug: misoprostol | Arm Label: misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol, Drug: placebo | Intervention Type: DRUG; Name: mifepristone; Assigned to Arm(s): mifepristone+misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): mifepristone+misoprostol, misoprostol | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): misoprostol
C: Arm Label: Mifepristone-misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone and misoprostol | Intervention Type: DRUG; Name: Mifepristone and misoprostol; Assigned to Arm(s): Mifepristone-misoprostol
D: Arm Label: In-Center Use of Mifepristone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Out-of-Center Use of Mifepristone; Type: EXPERIMENTAL; Interventions: Drug: Mifepristone | Intervention Type: DRUG; Name: Mifepristone; Assigned to Arm(s): Out-of-Center Use of Mifepristone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chemomechanical Caries Removal Using a Papain-Based Gel: A Randomized Clinical Trial
Brief Summary: To evaluate the efficacy of a papain-based gel in caries removal.


Options:
A: Arm Label: SW intervention; Type: EXPERIMENTAL; Interventions: Procedure: SW | Arm Label: DCE intervention; Type: OTHER; Interventions: Procedure: DCE | Intervention Type: PROCEDURE; Name: SW; Assigned to Arm(s): SW intervention | Intervention Type: PROCEDURE; Name: DCE; Assigned to Arm(s): DCE intervention
B: Arm Label: CHEMOMECHANICAL CARIES REMOVAL; Type: EXPERIMENTAL; Interventions: Procedure: Chemomechanical Caries Removal | Arm Label: conventional method; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional method | Intervention Type: PROCEDURE; Name: Chemomechanical Caries Removal; Assigned to Arm(s): CHEMOMECHANICAL CARIES REMOVAL | Intervention Type: PROCEDURE; Name: Conventional method; Assigned to Arm(s): conventional method
C: Arm Label: Hall Technique; Type: EXPERIMENTAL; Interventions: Procedure: Hall Technique | Arm Label: Non-Restorative Caries Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Non-Restorative Caries Treatment | Arm Label: Conventional Restoration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Restoration | Intervention Type: PROCEDURE; Name: Hall Technique; Assigned to Arm(s): Hall Technique | Intervention Type: PROCEDURE; Name: Non-Restorative Caries Treatment; Assigned to Arm(s): Non-Restorative Caries Treatment | Intervention Type: PROCEDURE; Name: Conventional Restoration; Assigned to Arm(s): Conventional Restoration
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Partial removal of carious dentine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Stepwise excavation | Intervention Type: PROCEDURE; Name: Partial removal of carious dentine; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Stepwise excavation; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Oral Sucrose and Topical Anesthetics to Reduce Pain During Eye Examination
Brief Summary: Oral sucrose reduces pain during heel sticks and venipunctures in preterm infants. The purpose of this study was to determine the effectiveness of local anesthetic eye drops and a pacifier, plus repeated doses of 24% sucrose, to relieve pain associated with eye examinations for retinopathy of prematurity.


Options:
A: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A
B: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: N2O | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: oxygen | Intervention Type: OTHER; Name: N2O; Assigned to Arm(s): A | Intervention Type: OTHER; Name: oxygen; Assigned to Arm(s): B
D: Arm Label: oral sucrose solution; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Steril water | Arm Label: steril water; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Oral sucrose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: Oral sucrose solution; Assigned to Arm(s): steril water | Intervention Type: DIETARY_SUPPLEMENT; Name: Steril water; Assigned to Arm(s): oral sucrose solution

Answer: D